Erlotinib is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor, but the development of erlotinib resistance during chemotherapy can lead to treatment failure. To shed light on the erlotinib-resistant pathway, this study investigated the effect of combination therapy using curcumin-and erlotinib-loaded nanoparticles on the expression of α v β 3 integrin and pyruvate dehydrogenase kinase 4 (PDK4) in an erlotinib-resistant SW480 colon cancer cell line. An erlotinib-resistant SW480 colon cancer cell line was produced by long-term exposure to erlotinib. Curcumin-loaded Methoxy poly ethylene glycol Poly caprolactone (cur/mPEG-PCL) and erlotinib-loaded mPEG-PCL (erl/mPEG-PCL) micelles were provided using a single step nanoprecipitation method and used as combination therapy of resistant SW480 cancer cells. After that, gene expression levels of PDK4, αv, and β3 mRNA were determined by the semiquantitative reverse transcription-polymerase chain reaction.
| INTRODUCTION
Colorectal cancer (CRC) is known as a major public health problem, with an annually global burden of about 1.2 million of new cases (Schreuders et al., 2015) . Although chemotherapy is the pivotal treatment of CRC, its application is limited by drug resistance, which is a major impediment in medical oncology (Holohan, Van Schaeybroeck, Longley, & Johnston, 2013; Townsley et al., 2006) . Various mechanisms are thought to induce cancer cell resistance, including alterations in drug transport and metabolism, mutations, and amplification of drug targets, as well as genetic rewiring (Longley & Johnston, 2005; Zahreddine & Borden, 2013) .
In this regard, targeting of molecular agents, which specifically modulate drug resistance in malignant cells, has opened up new possibilities in cancer treatment (Porębska, Harłozińska, & Bojarowski, 2000) . Erlotinib is an orally active drug, which works by selective inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase.
Erlotinib resistance during chemotherapy leads to treatment failure (Sos et al., 2009) . Studies have shown that transformation of differentiated cancerous cells to a stem-like phenotype is one of the major causes of drug resistance (Li C. et al., 2007; Singh & Settleman, 2010) . During the epithelial-mesenchymal transition (EMT) process, epithelial cells prevent the expression of epithelial-specific markers and induce the expression of mesenchymal markers, leading to cells with distinctive morphological and migratory properties (Singh & Settleman, 2010) . Accordingly, one study revealed that metabolic rewiring during the EMT process had resulted in the diversion of glucose to the tricarboxylic acid cycle and that was mediated by reduced expression of pyruvate dehydrogenase kinase 4 (PDK4) (Sun Y. et al., 2014) . Recent studies have also highlighted the role of integrin in the phenotypic transformation of cancer cells and the induction of drug resistance (Naci, Vuori, & Aoudjit, 2015; Seguin, Desgrosellier, Weis, & Cheresh, 2015) . The α v β 3 receptor is a member of the integrin family, which is markedly up regulated in CRC (Bohanes et al., 2015) .
Moreover, previous studies have demonstrated that the α v β 3 receptor was involved in cell survival, metastasis, angiogenesis, self-renewal, and erlotinib resistance signaling pathways, such as nuclear factor-kB, without any ligand binding (Cheresh, 2015; Seguin et al., 2015) . As well, another study demonstrated that α v β 3 was not only a marker/ driver of carcinoma stemness, but also a therapeutic target of EGFR inhibitors (Seguin et al., 2014) .
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is a natural derivative of turmeric, with chemopreventive and anticarcinogenic effects (Noorafshan & Ashkani-Esfahani, 2013; Shanmugam et al., 2015) . Previous research have suggested that it reduces colon tumor cell growth by down regulation of EGFR gene expression (Chen, Xu, & Johnson, 2006) . In addition, treatment of B16F10 melanoma cells with curcumin down regulated α v β 3 integrin expression (Ray, Chattopadhyay, Mitra, Siddiqi, & Chatterjee, 2003) .
Due to reduced effects of curcumin on drug resistance in some types of cancers, a combination of drugs and this polyphenol are used to improve the response and sensitivity of cancerous cells to common therapies (Yamauchi, Izumi, Yamamoto, & Nomori, 2014; Yu et al., 2009 ). Despite the well-documented anticancer properties of curcumin, poor solubility of the molecule in aqueous solutions, lightmediated degradation, a short half-life, and an inconsistent performance in patients can restrict its application in CRC therapy. The design and construction of nanocarriers bearing curcumin could also increase its solubility and subsequent half-life, thereby enhancing its applicability in CRC treatment (Lee et al., 2014) .
Our previous research on colon cancer, together with that of others, has shown that growth factor receptors play a pivotal role in malignancy (Fathi, Taghikhani, Ghannadi-Maragheh, & Yavari, 2013; Fathi, Yavari, Taghikhani, & Ghannadi, 2015) . However, the involvement of integrin and PDK4 in mechanisms underlying resistance in cancer remains unclear. According to the literature, curcumin influences α v β 3 integrin expression and plays a key role in erlotinib resistance. However, there have been no studies on the effects of nanoparticles bearing curcumin on α v β 3 integrin expression in an erlotinib-resistant colon cancer cell line. To shed light on the erlotinib-resistant pathway, this study examined the effects of combination therapy with curcumin-and erlotinib-loaded nanoparticles on the expression of α v β 3 integrin and PDK4 in an erlotinib-resistant SW480 cancer cell line. We hypothesized that a combination of nanoparticles carrying curcumin and erlotinib would reduce drug resistance via down-regulation of α v β 3 integrin expression and up regulation of PDK4 expression.
| MATERIAL AND METHODS

| Cell line and chemicals
The human colon cancer SW480 cell line (ATCC: CCL-228) was obtained from Pasteur Institute of Iran (Tehran, Iran) and cultured in RPMI 1640 medium (Gibco, Scotland), supplemented with 10% fetal bovine serum (Gibco, Scotland), 1% penicillin-streptomycin (Gibco, Scotland), and 5% CO2 at 37°C. To establish a drug-resistant SW480 cell line, cells were cultured continuously in the presence of increasing concentrations of erlotinib. The starting drug dose was 2.5 μM, and exposure doses were doubled every 15 days until reaching a final concentration of 20 μM. The cells were maintained in continuous culture with the final dose of erlotinib (20 μM) for 30 days (Ghosh, Yan, Lee, Kron, & Palecek, 2010 ). An mPEG-PCL di-block copolymer was synthesized via ring-opening polymerization of caprolactone in the presence of mPEG according to our previous report (Danafar, Davaran, Rostamizadeh, Valizadeh, & Hamidi, 2014) . Curcumin (Merck, Darmstadt, Germany, Art No. 820354) and stannous 2-ethyl-hexanoate (Sn(Oct) 2 ; Sigma Aldrich, St. Louis, USA, CAS. 301100) were all purchased locally. Other chemicals and solvent were analytical grades and purchased locally and then used as received.
| Preparation of curcumin-loaded nanoparticles
Curcumin-loaded Methoxy poly ethylene glycol Poly caprolactone (cur/mPEG-PCL) micelles were prepared using a single-step nanoprecipitation method (Danafar et al., 2014) . Curcumin (0.14 mg) and the mPEG-PCL di-block copolymer (0.8 mg) were codissolved in 400 μl of acetonitrile. This solution was then poured drop-wise through a syringe (G = 22) into 4 ml of distilled water in an ultrasonic bath.
| Preparation of erlotinib-loaded nanoparticles
Erlotinib-loaded mPEG-PCL (erl/mPEG-PCL) micelles were prepared using the method described above, with a mixture of methanol and acetone used as the solvents. Briefly, an mPEG-PCL copolymer (0.8 mg), and erlotinib (0.14 mg) were dissolved in a mixture of methanol and acetone (methanol acetone ratio of 1:2; 400 μl). The solution was then poured drop-wise through a syringe (G = 22) into 4 ml of distilled water in an ultrasonic bath. Entrapment efficiency (drug loading and total dried nanodispersion weight) was obtained using the following equation:
| Determination of particle size
where EE% was the efficiency of entrapment (percent), W t micelles was the total mass of powder obtained after freeze drying, and W feed drug was the feed drug initially used in the preparation of the micelles.
| MTT viability assay
The SW480 cell line and resistant line were cultured at 37°C in a humidified incubator under 5% CO2 pressure. Then, inhibition of cell proliferation was measured using an MTT assay. The cultured cells were seeded in 96-well plates at a density of 8 × 10 3 cells per well in triplicates. After 24 hr, 40 μl of MTT solution (5 mg/ml in phosphate buffer saline (PBS)) were added to each well and incubated for 3 hr.
The supernatants were then aspirated carefully, and 200 μl of dimethyl sulfoxide were added to each well. The plate was shaken for an additional 10 min. Finally, the absorbance value was read at 570 nm using a Stat Fax-2100 microplate reader (Awareness Technology, USA).
Cell viability was calculated as a percentage using the formula:
(mean Optical Density (OD) of treated cells/mean OD of control cells) × 100. The results were expressed as the percentage of the control cells, which was not treated. To calculate the IC50, different doses of curcumin and erlotinib were added to the SW480 and resistant cell
lines. An MTT assay was also performed as described above, and absorbance was plotted against the drug concentrations for both drugs. The concentration at which the viability reached 50% was defined as the IC50.
| Drug treatment
The resistant cancerous cells were treated with different doses of curcumin and erlotinib, with seven groups in total (Table 1) . It should be noted that the doses of curcumin and erlotinib were based on the obtained IC50.
| RNA isolation and reverse transcriptionpolymerase chain reaction
After being cultured and treated, total RNA from the cells in the groups and subgroups (Table 1) was extracted using QIAzol lysis reagent (QIAGEN Inc., Valencia, CA, USA) according to the manufacturer's instructions followed by DNase-I treatment. Moreover, RNA quantification was assessed at 260 nm using an ND-1000 spectrophotometer (Nano Drop, Wilmington, DE, USA), and RNA quality (integrity) was checked by 1% agarose gel electrophoresis. One microgram of total RNA from each cell group and subgroup was retro-transcribed into cDNA using Prime-Script cDNA synthesis reagents (Takara Bio, Inc., Japan), adjusted in a total reaction mixture of 20 μl. In addition, polymerase chain reaction (PCR) was performed in a FlexCycler 2 system ; Nano-particles containing 3 μM curcumin B2; Nano-particles containing 6 μM curcumin B3; Nano-particles containing 9 μM curcumin C) NP3C + NPEr C1; Nano-particles containing 3 μM curcumin and 5 μM Erlotinib C2; Nano-particles containing 3 μM curcumin and 10 μM Erlotinib C3; Nano-particles containing 3 μM curcumin and 15 μM Erlotinib D) NP6C + NPEr D1; Nano-particles containing 6 μM curcumin and 5 μM Erlotinib D2; Nano-particles containing 6 μM curcumin and 10 μM Erlotinib D3; Nano-particles containing 6 μM curcumin and 15 μM Erlotinib E) NP9C + NPEr E1; Nano-particles containing 9 μM curcumin and 5 μM Erlotinib E2; Nano-particles containing 9 μM curcumin and 10 μM Erlotinib E3; Nano-particles containing 9 μM curcumin and 15 μM Erlotinib F) NP Nano-particle polymer without any drug (Biometra GmbH, Germany), with 1 μl of cDNA and 50 pmol of each primer corresponding to the genes of interest. Finally, the expression assays were run in duplicate and repeated three times. The genes of interest were α V β 3 and PDK4, and β-actin was used as an internal control.
The primer pairs used were as follows: α V : F (Forward) 5′-TGGA ACTCAACTCTTAGCTGG-3′, R (Reverse) 3′-TCCTCTTATCTCAACT GCAGC-5′; β 3 : F5′-TAATAGCCATCGCTGCAACA-3′, R3′-ATCTTG CCAAAGTCACTGCT-5′, PDK4: F5′-GATTGGAGAGAGAGAATTG CC-3′; R3′-TGGATGCCTTTGGATTACC-5′; β-actin: F5′-TTCCTTCCT GGGCATGGAGT-3′, R3′-TACAGGTCTTTGCGGATGTC-5′.
Amplification was performed for 36 cycles (95°C, 45 s; 58°C, 45 s; 72°C, 60 s), with initial heating at 95°C for 5 min and a final extension for 5 min at 72°C. PCR products were run on 2.5% agarose gels (Invitrogen, USA), followed by visualization under a transilluminator after staining by Gel Red gel stain (Biotium, USA; cat. no. 41003).
Gel images were obtained, and the intensity of PCR product bands on these images was quantified using Total Lab gel analysis software.
The PCR product size was 172 BP for α V , 219 BP for β3, and 178 BP for PDK4.
| Protein extraction and α v β 3 expression in SW480 cells
The α v β 3 protein level was measured by the enzyme-linked immunosorbent assay (ELISA) method. In brief, treated cells in the different groups and subgroups (Table 1 ) and untreated cells (controls) were lysed in mammalian cell lysis buffer (10 ml of 1 × RadioImmunoPrecipitation Assay (RIPA) containing protease inhibitors), which was prepared by adding 10 μl of 1 mg/ml of leupeptin, 10 μl of 1 mg/ml of aprotinin, 10 μl of 1 mg/ml of pepstatin, 100 μl of 100 mM PMSF, and 1 ml of 10 × RIPA to 8.87 ml of distilled or deionized water after 48 hr posttreatment. The total protein concentration was determined in lysates using the Bradford assay. Moreover, the protein levels in the treated and control cells were determined using an α V β 3 ELISA Kit (R&D systems; cat. no. DYC3050-2) according to the instruction manual. In brief, equal amounts of total protein were added to 96-well microplates coated with a specific mouse monoclonal capture antibody. After being washed, the wells were incubated with a specific rabbit anti-α V β 3 antibody to detect the captured α V β 3 on the plate well. The wells were then washed, followed by incubation with a horseradish peroxidase-conju- 
| Statistical analysis
The Kolmogorov-Smirnov test was performed to test the normality of the data. PDK4 data showed a normal distribution. A one-way ANOVA was conducted to assess differences among the subgroups, followed by a post hoc test. Differences between two variables were measured by an independent sample t-test. The data did not follow a normal distribution for α v and β 3 and the Kruskal-Wallis test was performed to assess differences among the subgroups, and the Mann-Whitney test was conducted to assess between-group differences.
3 | RESULTS
| Establishment of a resistant SW480 colon cancer cell line
The cell viability percentage on the 15th day of exposure of erlotinib was 76.6 ± 2.3 at a dose of 2.5 μM, 84.2 ± 1.5 at a dose of 5 μM,
92.1 ± 3.7 at a dose of 10 μM, and 93.9 ± 1.9 at a dose of 20 μM (Figure 1 ). The increased viability of the cells in response to different concentrations of erlotinib, in addition to significant differences observed over time, pointed to cell adaptation and induced resistance.
As shown in Figures 2 and 3 , the IC50 for erlotinib in nonresistant cells was 89.5 ± 1.2 nM, whereas it increased to 18.6 ± 1.4 μM in the resistant cells, confirming resistance.
3.2 | Effects of curcumin on the viability of nonresistant and resistant SW480 cell line showing that nonresistant cells are more sensitive to erlotinib.
| Preparation and characterization of copolymeric micelles
The size of the nanoparticles was measured by the dynamic light scattering technique. As shown in supplementary Figure 1a and 1b, the z-average and zeta potential of the cur/PEG-PCL micelles were about 84.84 ± 0.2 nm and −13.3 ± 1.2 mv, respectively, with their corresponding PDI being 0.150 ± 0.2. As shown in Figure 1c and 1d, the z-average and zeta potential of the erl/mPEG-PCL micelles were about 78.60 ± 1.5 nm and −3.42 ± 0.7 mv, respectively, with their corresponding PDI being 0.148 ± 0.17. The drug loading and encapsulation efficiency of the cur/mPEG-PCL micelles were 3.6 ± 0.37% and 92.25 ± 2.78%, respectively, whereas the drug loading and encapsulation efficiency of the erl/mPEG-PCL micelles were 6.87 ± 1.53% and 95.36 ± 3.11%, respectively.
3.4 | Comparison of pyruvate dehydrogenase kinase 4, α v, and β 3 integrin expression in nonresistant and resistant SW480 cells and C3 than C2 (p = .05). In the E group, PDK4 expression significantly increased in subgroup E1 compared with E3 (p < .01). It also significantly increased in subgroup E2 compared with E3 (P < 0.05).
Comparison of between-group differences in PDK4 expression within subgroups revealed a significant increase in C1 compared with B1 (p < .001), B2 compared with D2 and D3 (p < .05), and B3 compared with E3 (p = .01). In addition, PDK4 expression was significantly elevated in C1 compared with D1 (p = .01), C3 with D3 (p < .05), C1
with E1 (p < .01), C3 with E3 (p = .001), and D3 with E3 (p < .05). At overall, the results showed that combination treatment with cur/ mPEG-PCL at a dose of 3 μM and erl/mPEG-PCL at a dose of 5 μM (Group C and Subgroup C1, respectively) had the most significant effects on PDK4 overexpression in resistant cells as compared with those in untreated resistant cells.
| Curcumin mediated down regulation of β 3 expression in resistant SW480 cells
Semi-quantitative analysis using reverse transcription-polymerase chain reaction indicated that β 3 expression was significantly different among the subgroups in the B, C, D, and E groups (p < .05), as shown in Figure 5a and 5b. Among the B1, B2, and B3 subgroups, only cur/ mPEG-PCL at a dose of 9 μM (B3) resulted in a significant decrease in mRNA expression of β 3 integrin in comparison to untreated resistant cells (p = .01), whereas curcumin at a lower dose (B1) caused the β 3 integrin to increase, indicating the importance of higher doses of 3.7 | Integrin α v β 3 protein increased in resistant SW480 cells and decreased after combination therapy using curcumin and erlotinib
After the combination treatment with cur/mPEG-PCL and erl/mPEG-PCL micelles, the level of β3 mRNA decreased, whereas that of αv mRNA either did not change or increased in some subgroups as compared with that of untreated resistant cells. Figure 6 presents the results of the ELISA of whole αvβ3 gene expression at the protein level 0.96 ± 0.08 ng/ml, respectively; p < .001). Taken together, combination therapy using cur/mPEG-PCL at a dose of 3 μM and erl/mPEG-PCL at a dose of 10 μM (C2) had the greatest effect on down regulation of the expression of the α v β 3 integrin protein in resistant colon cancer cells.
| DISCUSSION
To the best of our knowledge, this is the first study in which an erlotinib-resistant colon cancer cell line was established and used to assess the effects of curcumin-bearing nanoparticles on the expressions of α v β 3 integrin and PDK4, both of which as important players in cancer drug resistance. In this respect, a previous study showed that an aqueous formulation of cur/mPEG-PCL micelles markedly inhibited the growth of colon carcinomas (Gou et al., 2011) .
In this study, the erlotinib-resistant SW480 colon cancer cell line was developed by increasing the concentration of erlotinib. A nonsmall lung cancer cell line resistant to the EGFR inhibitor had been previously constructed (Ghosh et al., 2010) . In this study, the erlotinib IC50 for colon cancer-resistant cells was 19.1 μM, whereas it was 20 μM for non-small lung cancer cell line in the previous study (Ghosh et al., 2010) . The difference in the IC50 may be related to various factors, including different EGFR mutations in cancer cells, cell types, drug delivery systems, and passage numbers of cells.
In this study, PDK4 mRNA expression was not significantly differ- Drug resistance can also decrease the effectiveness of therapy and it is considered as a major challenge in cancer treatment (Housman et al., 2014) . Recent studies of cancerous cells have shown that the EMT have resulted in the differentiation of some types of cells into a stem-like phenotype, which can lead to drug resistance (Xiao & He, 2011) . The process was initiated by up regulation of α v β 3 integrin and down regulation of PDK4 gene expression, which diverted glucose to the tricarboxylic acid cycle (Seguin et al., 2014; Sun Y. et al., 2014) .
Given the close association between α v β 3 integrin, as well as PDK4
with erlotinib resistance, altering the expression of these genes holds the potential to prevent or increase the response to drug therapy.
Previous studies of breast, pancreatic, and lung cancer cells have demonstrated the involvement of β 3 integrin up regulation in the development of the resistance process. Consequently, the integrin subunit is used as a marker of cancer cells with stem-like properties that are resistant to erlotinib (Seguin et al., 2014) . The expression of β 3 mRNA increased 6.6-fold after the induction of resistance in SW480 colon cancer cells and decreased after combination therapy with curcumin and erlotinib-loaded nanoparticles. However, in this study, mesenchymal cluster of differentiation markers were not measured after the induction of resistance and combination therapy which could be another confirmation of such concept.
Accumulating evidence suggests that the metabolic system plays a key role in drug resistance (Rahman & Hasan, 2015) . Studies of oxidative decarboxylation of pyruvate in lung, prostate, and breast cancer cells have also suggested that down regulation of PDK4 can contribute to drug resistance (Sun Y. et al., 2014) . Curcumin is a natural polyphenol, which has anticancer properties and few side effects. Despite the safety and broad pharmacological effects of curcumin, its clinical applications have been hampered due to its extremely low aqueous solubility, instability, poor oral bioavailability, and rapid metabolism (Safavy et al., 2007; Sun M. et al., 2012) . In this respect, a previous study reported that curcumin nanoparticles were effective in suppressing tumor growth, proliferation, and angiogenesis in colon cancer (Gou et al., 2011) . Researchers also suggested that nanoparticles of curcumin could be a potential treatment strategy for colon cancer. Earlier research has also demonstrated that curcumin resulted in up regulation or down regulation of different genes in various signaling pathways (Shanmugam et al., 2015) . Furthermore, evidence suggested that exposure of a lung cancer cell line to curcumin and erlotinib could decrease drug resistance (Li S. et al., 2013) . In one study, a curcumin-treated B16F10 melanoma cell line showed a marked reduction in the expression of α 5 β 1 and α v β 3 integrin receptors (Ray et al., 2003) . In this study, in response to combination therapy with curcumin and erlotinib bearing nanoparticles, β 3 gene expression was down regulated, and α v mRNA expression was up regulated. Given that the α v subunit is the same between different integrin-bearing α v , we hypothesized that other integrins bearing the α v subunit might be up regulated at the cell surface in a SW480 erlotinib-resistant cell line. For this reason, we analyzed the whole α v β 3 integrin protein to determine the effect of the β 3 subunit on the resistance process, which was reduced with the cur/mPEG-PCL and erl/mPEG-PCL combination therapy. The results revealed that the whole protein of the α v β 3 integrin increased in resistant cells and decreased after combination therapy with curcumin and erlotinib.
In conclusion, the results of this study suggested that combination therapy with curcumin and erlotinib could decrease α v β 3 integrin and increase PDK4 gene expression, which may influence drug resistance signaling pathways. These findings suggested that the use of a combination of cur/mPEG-PCL and erl/mPEG-PCL could lead to a decline in the therapeutic dose of curcumin, implying that curcumin could help in overcoming the development of resistance by affecting the cognate drug.
This study had some limitations. Most importantly, this was an in vitro study. Therefore, the results cannot be directly transposed to animals or humans. In addition, we did not directly measure mesenchymal cluster of differentiation markers after the induction of resistance or combination therapy. 
